Human term placental cytosol fractions decreased the specific binding of gonadotrophin-releasing hormone (GnRH) isoform tracers to placental membranes (and to rat pituitary GnRH receptors and anti-GnRH antibodies) in a dose-dependent manner, and in parallel to GnRH standard curves. However, cytosol fractions had little or no effect on the binding of two GnRH superagonist tracers. The specificity of placental binding sites for a range of GnRH-like and unrelated peptides was shown to be similar with GnRH isoforms or GnRH agonists as binding ligands, suggesting that isoforms and agonists did not bind to different forms of the GnRHreceptor. Inclusion of a cocktail of protease inhibitors during the preparation of placental cytosol significantly reduced immuno-and receptor-binding activity. Moreover, incubation of radiolabelled chicken GnRH II with placental cytosol led to marked inactivation of tracer, as assessed by radioreceptor and radioimmunoassays for GnRH, high resolution liquid chromatography, thin layer chromatography and adsorption to dextrancoated charcoal and other matrices. There was a good negative correlation between tracer degradation and apparent GnRH immuno-and receptor-binding activities. These results emphasize the important effects which proteases in un-denatured tissue extracts can have on radioreceptor and radioimmunoassays due to inactivation of peptide tracers, and suggest that previous measurements of receptor-and immuno-active GnRH-like factors may have been over-estimated due to peptidase action during the GnRH assay.
Introduction
, including the human Gonadotrophin-releasing hormone (GnRH) acts in an autocrine/ (White et al., 1998) , suggesting that other GnRH isoforms in paracrine fashion as one factor in a complex regulatory addition to mGnRH may exist in extra-pituitary tissues, e.g. system (Petraglia, 1997) which controls the secretion of a placenta. Moreover, we have shown previously that some [ 125 I]-number of hormones by the human placenta (Merz et al., labelled GnRH isoforms (sGnRH ϭ cGnRH II Ͼ mGnRH ϾϾ 1991; Siler-Khodr et al., 1991; Barnea et al., 1992) . RadiocGnRH I ϭ lGnRH I) bound specifically to human placental labelled GnRH analogues bind specifically, and with moderate membranes, but not to rat pituitary membranes (Bramley affinity, to human placental membranes (Currie et al., 1981; . Binding of salmon GnRH (sGnRH) and chicken Belisle et al., 1984; Iwashita et al., 1986; Bramley et al., GnRH (cGnRH) II compared favourably with that of the 1992). The GnRH receptor gene is expressed in cytotrophoblast GnRH superagonists, ] GnRH ethylamide and syncytiotrophoblast cells (Lin et al., 1995; Wolfahrt et al., ([D-Trp 6 ] GnRH EtA) at all stages of gestation (Bramley 1998), and appears to be similar to that expressed in the human et al., 1994) . pituitary (Kakar et al., 1995; Leung and Peng, 1996) . Moreover, GnRH radioreceptor or radioimmunoassays are sensitive to the gene for mGnRH is expressed in human placenta (Seeburg interference from peptidases which degrade components of and Adelman, 1984; Seeburg et al., 1987; Radovick et al., the assay (hormone tracer, antibody, receptor), giving the 1990; Duello et al., 1993; Wolfahrt et al., 1998) , and appears appearance of immuno-or receptor-active GnRH-like activity identical to the hypothalamic peptide (Osathanondh and (Siler-Khodr et al., 1989) . Hence, studies of extrapituitary Elkind-Hirsch, 1981; Tan and Rousseau, 1982; Seeburg et al., GnRH often begin by extraction with denaturing agents (hot 1987; Zhuang et al., 1991) , although GnRH-like peptides organic acid; extraction with alcohols or acetone) which give (Mathialagan and Rao, 1986a,b; ; Zhuang a good yield of the GnRH decapeptide, but almost certainly et al., 1991) have also been isolated from human placental destroy the larger molecular weight forms of GnRH. Although tissue.
human placental extracts do indeed inactivate [ 125 I]-labelled More recently, post-translationally modified variants of GnRH analogues (Menzies and Bramley, 1992 ; Bramley and GnRH have been described in placenta (Gautron et al., 1989; Menzies, 1996) , other studies in our laboratory have suggested Currie et al., 1992) , and other forms of GnRH have been shown to be present in mammals (mGnRH; Rissman et al., the presence of a large, heat-labile GnRH-like activity in human omitted from preparative buffers, as these may affect the placental placental extracts which is unrelated to GnRH-degradation GnRH/GnRH receptor system (Bramley et al., 1999) . Aliquots (2 ml) (T.A.Bramley and M.Mullen, unpublished data).
of homogenate were snap-frozen in solid CO 2 , and stored at -20°C
Since we wished to identify and purify all form(s) of GnRH until required.
and GnRH-like factors secreted by the human placenta, we first Placentae required a robust assay which would enable the measurement of Human placentae were obtained from normal women following various GnRH forms by radioimmunoassays and/or radiorecepspontaneous vaginal delivery (n ϭ 12) or elective Caesarian section tor assays in fractions from un-denatured human placental at term (n ϭ 1). Placentae from early gestation pregnancies (8 weeks) extracts. In the course of these studies, the impact of inactivawere terminated using Mifepristone (RU 486) followed by induction tion of the radiolabelled GnRH tracers utilized became of labour using Gemeprost pessaries (Norman et al., 1992 
Materials and methods
and villi were minced and homogenized in ice-cold SET buffer (5 ml/g) using a Polytron homogenizer (two 10 s bursts at full speed, Materials separated by a 1 min cooling period in ice). After filtration through Sephadex G25 (fine) was obtained from Pharmacia Ltd (Milton four layers of cheesecloth, homogenates were centrifuged at 1000 g Keynes, Bucks, UK), and from Sigma Chemical Co Ltd (Poole, for 10 min (4°C) to remove nuclei and cell debris. Supernatants were Dorset, UK). QAEA-sepharose and CM-sepharose were obtained re-centrifuged at 100 000 g for 60 min in a Sorvall OTD-50 from Pharmacia. Thin layer chromatography (TLC) plates (polyethylrefrigerated ultracentrifuge (4°C). The microsomal pellets obtained eneimine cellulose on polyester backing, with or without fluorescent were gently rehomogenized (5-10 strokes in a loose Dounce homogenindicator) were obtained from Sigma. All other fine chemicals, izer) in SET medium, and supernatants (cytosol) and membranes enzyme inhibitors and reagents were from either Sigma or BDH were stored in 2 ml aliquots at -70°C or in liquid nitrogen. (Poole, Dorset, UK). Radiolabelled sodium iodide (Na 125 I) was obtained from Amersham International plc (Little Chalfont, Bucks, Methods UK).
Protein was measured by a previously described method (Lowry Lamprey GnRH I (lGnRH I) and salmon GnRH (sGnRH) Binding of radiolabelled GnRH agonists and isoforms to human the kind gift of Dr J.Sandow (Hoescht AG, Frankfurt, Germany). All placental membranes was measured by incubation of triplicate other GnRH analogues were purchased from Sigma. A conformationaliquots (0.5-1.0 mg protein/tube) at 20°C for 1 h in a 0.5 ml dependent anti-GnRH antibody (R 1245, which recognizes all isoforms incubation system containing 40 mmol/l Tris-HCl, pH 7.4, 0.5% of GnRH except lGnRH I) was the kind gift of Dr G.D.Niswender BSA and 100 000 cpm of the appropriate [ 125 I]-labelled GnRH tracer. (Fort Collins, Colorado, USA; see Bramley et al., 1992) and a second Non-specific binding was measured in duplicate in the presence of GnRH-specific antibody (HU 60) was the generous gift of Dr Henry 10 µg of unlabelled buserelin. Bound hormone was recovered by Urbanski (Oregon Regional Primate Center, Portland, OR, USA).
immunoglobulin G (IgG)-polyethyleneglycol (PEG) precipitation The specific anti-cGnRH II antibody (Ab 10.2; Sharp et al., 1987 ) (Bramley et al., 1985 , and pellets counted for 125 I in a Packard was a gift of Professor P. Sharp (Roslin Institute, Scotland, UK) .
Cobra™ II γ-counter (Meriden, CT, USA) at an efficiency of 75%.
Preparation and measurement of specific activities of [ 125 I]-
The difference between binding in the presence and absence of labelled GnRH tracers unlabelled GnRH agonist represented specific binding (normally Peptides were radioiodinated using a glucose oxidase/lactoperoxidase adjusted to 15-35% of total counts added). Controls without tissue, method, and were purified by chromatography on Sephadex G25 with and without unlabelled GnRH agonist, were included to correct columns (Bramley et al., 1992) . Specific activities of radiolabelled for displacement of tracer from assay tubes by cold analogue (usually mono-iodinated GnRH isoform preparations were estimated by a self-0.5-1% of total counts added). displacement assay (Clayton, 1983) using the conformation-dependent Specific binding of [ 125 I]-labelled GnRH agonists to rat pituitary anti-GnRH antibody (R 1245; 85-1100 Ci/g; n ϭ 9 separate GnRH homogenates or membranes was measured as described above, except isoform preparations). Specific activities of GnRH agonist tracers that incubation was for 4 h at 4°C. were measured by self-displacement assay of binding to homogenates of immature female rat pituitary glands (350-1105 Ci/g, n ϭ 12
Measurement of GnRH tracer inactivation preparations).
Aliquots of placental cytosol (5-100 µl) were incubated in a 0. Aliquots (200 µl) of incubation media or dextran-charcoal supernatant Tris-1 mmol/l EDTA, pH 7.4 (SET medium; two glands/ml) using a loose-fitting all-glass Dounce homogenizer. Protease inhibitors were fractions (see below) were applied through a 1 ml injection loop to a BioRad (Hemel Hempstead, UK) HRLC 500 series liquid chromatograph system (RoSiL C18 HL 5 µm column; 0.46ϫ25 cm) and eluted isocratically (1.5 ml/min) for 10 min with 5% acetonitrile in TEAF (0.25 mol/l formic acid adjusted to pH 6.5 with triethanolamine; Sherwood et al., 1991) . Acetonitrile was then increased to 60% over 55 min (1% change per min). Fractions (1 ml) were collected and 125 I counted in a Packard Cobra™ II γ-counter at an efficiency of 75%.
Thin layer chromatography (TLC)
Aliquots (5 µl ist. However, the same placental extract had little or no effect of GnRH isoforms or agonists by 50% (IC 50 ) were calculated from plots of specific binding versus log 10 (placental extract added). (hpGnRH) in cytosol fractions may then compete preferentireceptor for a range of GnRH isoforms, agonists, antagonists and other peptides (with or without gonadotrophin-releasing ally for a GnRH isoform-specific state of the receptor, rather than to a GnRH agonist-binding state. We therefore extended activity), using both radiolabelled GnRH isoforms and agonists as binding ligands. our studies to compare the specificity of the placental GnRH- 0.07 Ϯ 0.01 mg protein respectively; n ϭ 6), though this to GnRH (Li et al., 1987) failed to compete for buserelin failed to reach statistical significance. (Figure 3B ) or cGnRH II binding ( Figure 3C ) to placental Since GnRH superagonists are designed to have increased membranes. Moreover, a number of peptides with an N-terminal resistance to proteolytic degradation (D-aminoacid substitupGlu (gastrin I, hydra peptide, neurotensin), a C-terminal tion at Gly 6 ; C-terminal ethylamide), an alternative explanaGly-amide (thymosin a1) or with both an N-terminal pGlu1 tion for the differences in potency of placental extracts and a C-terminal amide residue (thyrotrophin-releasing factor, towards binding of radiolabelled GnRH isoforms and agonists bombesin, gastrin II, physalaemin, serum thymic factor, (as well as the reduced immuno-and receptor-binding adipokinetic hormone II, caerulein, eledoisin, gastrin releasing activity of placental cytosol prepared with and without peptide, pancreastatin) did not compete for placental GnRH protease inhibitors) is that placental cytosol fractions possess binding sites (Figures 3B, C and unpublished data) . No inhibienzyme(s) capable of inactivating GnRH isoforms, but not tion was seen with other unrelated peptides (epidermal growth GnRH agonists. We therefore compared the effects of factor, oxytocin, insulin, angiotensin I, II and III; data not incubation of radiolabelled GnRH isoforms and agonists shown). These experiments indicated similar binding affinities with placental extracts using a variety of different techniques and specificities of placental membrane receptors with either to estimate loss of binding ligand integrity. radiolabelled GnRH agonists and GnRH isoforms.
Do GnRH isoforms and agonists bind differently to
High resolution liquid chromatography Term placental cytosol fractions also gave parallel displace-HRLC demonstrated a marked change in tracer integrity ment to GnRH isoforms in a GnRH-specific radioimmunofollowing incubation with cytosol, with the appearance of a assays ( Figure 4A ). Concentrations of cytosol required to major product having a much shorter retention time than intact inhibit specific binding of (Table I) . Moreover, placental cytosols from earlier stages of appearance of a novel peak ( Figure 5B ). However, the amount gestation (8, 15 and 16 weeks gestation) also showed high of novel product formed was much lower than with [ 125 I]-immunoactivity ( Figure 4B ). However, isolation of 15-week labelled cGnRH II, and more intact tracer remained, suggesting placental cytosol fraction in the presence of a cocktail of lower degradation of the agonist compared with the GnRH protease inhibitors markedly reduced GnRH-like immunoisoform. Treatment of tracer incubated in the absence of activity ( Figure 4B Figures 5A,B) . Thin layer chromatography was studied further by TLC on polyethyleneimine cellulose TLC plates. Degradation of cGnRH II and [D-Trp 6 ] GnRH Since HRLC was time-consuming, expensive and could handle only a few samples per day, the integrity of cGnRH II tracers
EtA tracers was markedly reduced by incubation at lower temperature (0°C) or with boiled cytosol (Table III) . Intact cGnRH II tracer, and tracer incubated in the absence of cytosol origin following TLC ( Figure 6B ; lane 1), and was adsorbed by DCC treatment (lane 2). An additional spot appeared after incubation with placental cytosol ( Figure 6B ; lane 3), but the may provide a rapid screen for the measurement of GnRH low R f of the product formed (R f Ͻ 0.05) made it difficult to tracer degradation. We therefore investigated adsorption of resolve from intact tracer remaining at the origin. However, intact and degraded GnRH tracers to different membranes and DCC adsorption of tracer incubated with placental extract chromatography gels. Ion exchange chromatography (DEAEdecreased the intensity of the spot at the origin (lane 4), and CM-sepharoses) of radiolabelled GnRH agonist and isoallowing the product to be seen clearly. Tracer was recovered forms following incubation with placental cytosol resolved at the origin after incubation with boiled cytosol ( Figure 6B ; intact and inactivated tracers, but resolution of degraded and lane 5), and was adsorbed by DCC (lane 6). Similar changes un-degraded peptides was variable and dependent on the ionic were seen with radioiodinated buserelin tracers (data not strength of the elution buffer (data not shown). shown).
[ 125 I]-labelled cGnRH II incubated without placental cytosol adsorbed strongly to Sephadex G25, eluting in a broad peak
Adsorption of [ 125 I]-labelled GnRH tracers
which was retarded beyond the total volume (V t ) of the column The data presented in Figures 5 and 6 suggested that differential adsorption of intact and inactivated tracers to dextrans or DCC ( Figure 7A,B) . Fractions from the tracer peak bound well to both a specific anti-cGnRH II antibody ( Figure 7A ) and a elution profiles to tracer incubated without cytosol, and bound well to both anti-GnRH antisera; data not shown. conformation-specific anti-GnRH antibody ( Figure 7B ), demonstrating that this peak was intact cGnRH II tracer. After Adsorption of cGnRH II and mGnRH tracer to Whatman filter paper, cellulose nitrate and nylon membranes was signiincubation with placental cytosol, however, the main peak of radioactivity was no longer retarded, but eluted in the total ficantly reduced by incubation with placental cytosol, but not by boiled cytosol (Table IV) . Incubation with cytosol had volume of the column (Figure 7C,D) . This material failed to bind to either anti-GnRH antiserum ( Figure 7C,D (Figures 6 and 7) . We therefore compared the effects of cytosol on degradation of cGnRH II tracer measured by DCC adsorption with the effects of cytosol in a human placental GnRH radioreceptor assay and a cGnRH II-specific radioimmunoassay. [ 125 I]-labelled cGnRH II not adsorbed by DCC increased in a dose-related manner with increasing cytosol concentration ( Figure 8A ). Placental cytosol also reduced [ 125 I]-labelled cGnRH II binding to term placental placental cytosol (lanes 3 and 4) or cytosol which had been boiled for 10 min (lanes 5 and 6). Other replicates were treated with Replicates of tracer incubated with cytosol were treated with icecold dextran-coated charcoal, centrifuged, and subjected to HRLC ice-cold dextran-coated charcoal, centrifuged at 3500 g for 10 min (4°C), and 5 µl aliquots of supernatant then spotted onto the plate (m,d). Fractions (1 min) of each chromatogram were collected and 125 I counted.
(lanes 2, 4 and 6). Discussion membranes ( Figure 8B ) and to anti-GnRH antibody (HU 60) in a dose-dependent manner ( Figure 8C ). (Figure 8D) C; Table I ). However, placental extracts failed to inhibit the indicated that displacement of tracer binding in the radiobinding of radiolabelled GnRH agonists to placental GnRHimmunoassays and radioreceptor assays was not due GnRHreceptors (Figures 1 and 2D ,E; Table I , although cytosol did receptor on unsedimented placental membrane vesicles in inhibit [ 125 I]-labelled GnRH agonist binding to rat pituitary cytosol fractions. There was a good negative correlation membranes at higher concentrations; Figure 2F and Table I ). between radioactivity recovered in the supernatant after DCC One possible explanation for the different effects of placental adsorption, and binding to both the placental membrane GnRHextracts on GnRH isoform and agonist binding to placental receptor ( Figure 8E ; r 2 ϭ -0.97 , P Ͻ 0.001) and to antimembranes is that isoform and agonist tracers bind differently to placental receptors (Tensen et al., 1997) , or to different GnRH antibody ( Figure 8F ; r 2 ϭ -0.98, P Ͻ 0.001). receptor subtypes (Troskie et al., 1998) , and that hpGnRH is properties of pituitary versus extra-pituitary GnRH receptors rather than species differences. Receptors with distinct binding more specific for the isoform-binding site than for the agonistbinding site. Despite human placental GnRH-receptor mRNA properties and/or ligand specificities may arise through expression of different GnRH receptor subtypes (Troskie et al., 1998) being very similar to that expressed in the pituitary gland (Kakar et al., 1995; Leung and Peng, 1997) , there are certainly or differential splicing of the gene, but to date, distinct forms of GnRH-receptor have not been reported in human placenta. differences in binding specificity (Table II) and affinity (Currie et al., 1981; Belisle et al., 1984; Iwashita et al., 1986; Bramley We failed to detect any significant differences of the human placental receptor in binding ligand affinity or specificity for et al., 1992, 1994) between rat pituitary and human placental GnRH-receptors. Moreover, other forms of GnRH are active a range of peptides, using both [ 125 I]-labelled GnRH isoforms or agonists as binding ligands. The different GnRH isoforms, in extra-pituitary human tissues (Gautron et al., 1989; Pati and Habibi, 1995) . However, the specificities and affinities of rat agonists and antagonists tested had similar specificity profiles for all radiolabelled tracers used to measure binding to placental and human pituitary GnRH receptors are similar (Wormald et al., 1985) , suggesting ligand specificity differences reflect membranes (Figure 3) . Interestingly, peptides with pGlu 1 and/ or C-terminal amides failed to affect binding of either GnRH immuno-and receptor-binding GnRH-like activity ( Figures  8E,F) . However, whilst resistance of agonist tracers to peptidase agonist ( Figure 3B ) or GnRH isoform ( Figure 3D ). Such peptides should compete for the active sites of pyroglutamyl degradation may account for the lack of effect of placental extract on the binding of agonists to placental membranes, peptidase and carboxypeptidase respectively. Hence, our data suggest that GnRH degradation under these conditions does these extracts did suppress binding of two GnRH agonist tracers to rat pituitary membranes ( Figure 2F ), suggesting that not involve these enzymes.
G-proteins are present in the human placenta, and guanine placental cytosol effects were not wholly attributable to tracer degradation. Indeed, the properties of C-ase 1 (Siler Khodr nucleotides can modulate the affinity of extra-pituitary GnRHreceptors (Segal-Abramson et al., 1992; Imai et al., 1996 Imai et al., ). et al., 1989 differ significantly from our data on human placental cytosolic GnRH-degrading activities, and although Thus, differences in G-protein state, or coupling of receptors to different G-proteins (Delahaye et al., 1997) , may account inclusion of peptidase inhibitors significantly reduces the effects of placental extracts on both radioreceptor and radiofor some of the differences observed between GnRH isoform and agonist binding. However, GTP, GDP, GMP, GTPγS, immunoassays, some hpGnRH-like activity persists under conditions of minimal GnRH tracer degradation (T.A.Bramley GDPγS, or cGMP at concentrations up to 5 mmol/l had no effect on displacement curves of [ 125 I]-labelled agonist or and G.S.Menzies, unpublished data). Such GnRH-like activity may be due to GnRH-binding protein(s) such as those in cGnRH II binding to placental membranes by unlabelled GnRH or GnRH agonists (data not shown), suggesting that G-protein previous reports (Flanaghan et al., 1996; Siler-Khodr et al., 1997) . The isolation of GnRH-like factors in undenatured coupling was not responsible for placental GnRH-receptor specificity differences.
placental extracts awaits the development and validation of robust GnRH radioimmunoassays and radioreceptor assays Although GnRH-like peptides have been isolated from extrapituitary tissues, and a GnRH-like factor was isolated from which are insensitive to peptidase interference. Studies of the effects of different protease inhibitors on the degradation of ovarian extracts of several species (including human; Aten et al., 1987) , this was subsequently shown to be a histone GnRH binding ligands (GnRH isoforms and agonists) may facilitate the development of such assays. protein (Aten and Behrman, 1989) . However, a number of different histones (at concentrations up to 10 µg per tube) failed to inhibit binding of [ 125 I]-labelled buserelin or cGnRH
